Stamford, CT -- (SBWIRE) -- 01/23/2014 -- Wall Street Pennies is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Generex Biotechnology Corporation (OTCMKTS:GNBT), Growlife Inc (OTCBB:PHOT), Cell Therapeutics Inc (NASDAQ:CTIC), Best Buy Co., Inc. (NYSE:BBY).
Generex Biotechnology Corporation (OTCMKTS:GNBT) opened its last trade at the price of $0.05. Its closing price was $0.0467 after gaining 3.78% for the day. The company traded with the total volume of 16.54 million shares, while its average trading volume remained 6.09 million shares. The beta of this stock stands at 2.12. Generex Biotechnology Corporation, a development stage company, is engaged in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases.
For How Long GNBT will Fight for Profitability? Read This Trend Analysis report
Growlife Inc (OTCBB:PHOT) percentage change surged 18.16% to close at $0.225 with the total traded volume of 59.56 million shares, along with average volume of 46.72 million shares. The 52 week range of the stock remained $0.00 - $0.47, while its day lowest price was $0.20. The share price hit the day highest price of $0.24. Growlife, Inc., through its subsidiaries, manufactures and markets horticulture and lifestyle products in the United States and internationally. It offers LED lights for indoor growing; wireless monitoring and control equipment to operate grow room functions; and plant growing systems and accessories, including nutrients, media, timers, controls, and automated water accessories.
Will PHOT Continue To Move Higher? Find Out Here
Cell Therapeutics Inc (NASDAQ:CTIC) traded on volume of 14.62 million shares in the last session against average volume of 5.15 million shares. The company started its trading session with the price of $4.11 and closed at $4.01 by scoring -4.75%. Cell Therapeutics, Inc. acquires, develops, and commercializes treatments for cancer. The company primary focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in Phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
Why Should Investors Buy CTIC After the Recent Fall? Just Go Here and Find Out
Best Buy Co., Inc. (NYSE:BBY) started its last trading session with the price of $24.59 and closed at $26.01 by scoring +6.29%. The stock traded with total volume of 23.74 million shares, while the average trading volume remained 10.56 million shares. The beta value of this stock stands at 1.27. Day range for the stock was $24.47 - $26.11. Best Buy Co., Inc. operates as an e-commerce and physical retailer of consumer electronics in the United States, Europe, Canada, and China. The company’s stores offer video products, including televisions, e-readers, navigation products, digital cameras and accessories, digital camcorders and accessories, and DVD and Blu-ray players; audio products.
For How Long BBY will Fight for Profitability? Read This Trend Analysis report
About Wall Street Pennies:
Wall Street Pennies is always penetrating the market every day for enormous penny stock runs before they happen in order to assist its customers. Our Penny Stock Newsletter also offers free market strategies and analysis from one of the most experienced and well-respected chartists in the penny stock industry.
Carriage Consulting Group, www.wallstreetpennies.com,, their Members, officers, directors, employees, affiliates, or any other related person(s) (collectively, “www.wallstreetpennies.com,”) are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. Wall Street Pennies as defined are neither licensed nor qualified to provide investment advice and you are specifically and adamantly advised not to rely upon anything said/posted/communicated/implied or expressed by www.wallstreetpennies.com, as defined.
Read full Disclaimer at: http://wallstreetpennies.com/financial-disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)